Salutary effect of gastric pentadecapeptide BPC 157 in two different stress urinary incontinence models in female rats
Ivan Jandric, Hrvoje Vrcic, Marica Jandric Balen, Danijela Kolenc, Luka Brcic, Bozo Radic, Domagoj Drmic, Sven Seiwerth, Predrag Sikiric
Med Sci Monit Basic Res 2013; 19:93-102
Since an originally anti-ulcer stable gastric pentadecapeptide BPC 157 (PL 14736) was shown to promote healing of injured striated muscle and smooth muscle in the gastrointestinal tract, we explored its therapeutic potentials for leak point pressure (LPP) recovery in rat stress urinary incontinence (SUI) after transabdominal urethrolysis (TU) and prolonged vaginal dilatation (VD).
Material and Methods: During a 7-day period, TU-rats and VD-rats (or healthy rats) received BPC 157, either (i) intraperitoneally, 10 µg/kg or 10 ng/kg, once daily (first administration 30 min after surgery, last 24 h before LPP-testing and sacrifice), or (ii) per-orally, 10 µg/kg in drinking water (0.16 µg/mL, 12 mL/rat/day). Vesicourethral segments were harvested for immunohistochemical evaluation.
Results: All BPC 157 regimens counteracted decrease of LPP values in TU-rats and VD-rats. Additionally, BPC 157-TU rats (µg-intraperitoneally or per-orally) and BPC 157-VD rats (µg intraperitoneally) reached LPP values originally noted in healthy rats. Conversely, in healthy rats, BPC 157 did not alter LPP. Immunohistochemical studies revealed higher desmin (delineates striated organization of skeletal muscle), smooth muscle actin, and CD34 (angiogenic marker) positivity within the urethral wall in BPC 157-treated rats vs. controls, as well as overall preserved muscle/connective tissue ratio assessed with Mallory’s trichrome staining.
Conclusions: Pentadecapeptide BPC 157, applied parenterally or per-orally, appears to ameliorate the SUI in rat models, improving the otherwise detrimental course of healing after VD and TU, which may be analogous to human injury. These beneficial effects may possibly be selectively used in future strategies for treatment of SUI.
Keywords: Rats, Proteins - therapeutic use, Peptide Fragments - therapeutic use, Muscle, Smooth - pathology, Infusions, Parenteral, Disease Models, Animal, Anti-Ulcer Agents - therapeutic use, Animals, Administration, Oral, Actins - metabolism, Rats, Wistar, Urethra - pathology, Urinary Incontinence, Stress - drug therapy, Vagina - pathology, Wound Healing